

References

S-206

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Chronic lymphocytic leukemia/Small lymphocytic lymphoma.1.2022.
2. Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J, Kumar A. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. *Hematol Oncol Stem Cell Ther.* 2018;11(2):53-64.
3. Roeker LE, Dreger P, Brown JR, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. *Blood Adv.* 2020;4(16):3977-3989.
4. Kim HT, Shaughnessy CJ, Rai SC, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. *Blood Adv.* 2020;4(17):4113-4123.
5. Farina L, Barretta F, Scarfò L, et al. Refractory and 17p-deleted chronic lymphocytic leukemia: Improving survival with pathway inhibitors and allogeneic stem cell transplantation. *Biol Blood Marrow Transplant.* 2020;26(10):e256-e262.